logo
Share SHARE
FONT-SIZE Plus   Neg

Astellas Pharma Says FDA Advisory Committee Recommends Approval Of Mirabegron

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (ALPMY.PK, ALPMF.PK), announced that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted that the overall risk/benefit assessment supports approval of mirabegron (YM178) for the treatment of overactive bladder (OAB) (Yes: 7, No: 4, Abstain: 1).

Today's committee recommendation, although not binding, will be considered by the FDA as it reviews the New Drug Application or NDA, the company said. The FDA is expected to issue an action letter on the mirabegron application by June 29, 2012.

Mirabegron is a once daily oral selective B3-adrenoceptor agonist discovered and developed by Astellas. Mirabegron has been studied extensively in more than 10,000 individuals over the last 10 years.

Mirabegron uses a distinct mechanism of action versus antimuscarinics, the current treatment standard. Antimuscarinics work by binding to muscarinic receptors in the bladder and inhibiting involuntary bladder contractions. Mirabegron works by stimulating the B3 receptors in the detrusor muscle of the bladder, causing relaxation of the bladder muscle during the storage phase of the micturition (urination) cycle. This improves the storage capacity of the bladder without diminishing bladder contraction during bladder voiding.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Tinder has launched a premium version of its popular dating app called Tinder Plus, which will cost users $9.99 each month, and double if they are over 30. In the US, Tinder Plus costs users $9.99 a month for users under 30 years, and $19.99 if users are over 30. Meanwhile, users under the age... European soft drinks and fruit juices bottler Refresco Gerber is pursuing initial public offering in Amsterdam to support its future growth. The firm which has been owned by private equity plans to list on Euronext. A new study shows that teens are able to easily buy e-cigarettes Online despite age restrictions. Teens could successfully have the nicotine-free e-cigarettes delivered to their doorsteps 94 percent of the time. Meanwhile, the sales of e-cigarettes, or vaping smokes, to young people under age 18 are already banned in a total of 41 states in the U.S.
comments powered by Disqus
Follow RTT